Literature DB >> 31406252

circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.

Yiran Liang1, Xiaojin Song1, Yaming Li1, Peng Su2, Dianwen Han1, Tingting Ma1, Renbo Guo3, Bing Chen4, Wenjing Zhao4, Yuting Sang1, Ning Zhang1, Xiaoyan Li1, Hanwen Zhang1, Ying Liu1, Yi Duan1, Lijuan Wang4, Qifeng Yang5,6.   

Abstract

Increasing evidence has indicated that circular RNAs (circRNAs) play a critical role in cancer development. However, only a small number of circRNAs have been experimentally validated and functionally annotated. In this study, using a high-throughput microarray assay, we identified a novel circRNA, circKDM4C, which was downregulated in breast cancer tissues with metastasis. Furthermore, we analyzed a cohort of breast cancer patients and found that circKDM4C expression was decreased in breast cancer tissues, and lower circKDM4C expression was associated with poor prognosis and metastasis in breast cancer. Functionally, we demonstrated that circKDM4C significantly repressed breast cancer proliferation, metastasis, and doxorubicin resistance in vitro and in vivo. Mechanistically, using a dual-luciferase activity assay and AGO2 RNA immunoprecipitation, circKDM4C was identified as a miR-548p sponge. We also found that PBLD was a direct target of miR-548p, which functioned as a tumor suppressor in breast cancer. Moreover, miR-548p overexpression was able to reverse the circKDM4C-induced attenuation of malignant phenotypes and elevated expression of PBLD in breast cancer cells. Taken together, our data indicate that circKDM4C might have considerable potential as a prognostic biomarker in breast cancer, and support the notion that therapeutic targeting of circKDM4C/miR-548p/PBLD axis may be a promising treatment approach for breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31406252     DOI: 10.1038/s41388-019-0926-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Mis-splicing yields circular RNA molecules.

Authors:  C Cocquerelle; B Mascrez; D Hétuin; B Bailleul
Journal:  FASEB J       Date:  1993-01       Impact factor: 5.191

Review 2.  Regulation of circRNA biogenesis.

Authors:  Ling-Ling Chen; Li Yang
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer.

Authors:  Jie Chen; Yan Li; Qiupeng Zheng; Chunyang Bao; Jian He; Bin Chen; Dongbin Lyu; Biqiang Zheng; Yu Xu; Ziwen Long; Ye Zhou; Huiyan Zhu; Yanong Wang; Xianghuo He; Yingqiang Shi; Shenglin Huang
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

4.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.

Authors:  Charissa Kim; Ruli Gao; Emi Sei; Rachel Brandt; Johan Hartman; Thomas Hatschek; Nicola Crosetto; Theodoros Foukakis; Nicholas E Navin
Journal:  Cell       Date:  2018-04-19       Impact factor: 41.582

5.  Circular RNAs are abundant, conserved, and associated with ALU repeats.

Authors:  William R Jeck; Jessica A Sorrentino; Kai Wang; Michael K Slevin; Christin E Burd; Jinze Liu; William F Marzluff; Norman E Sharpless
Journal:  RNA       Date:  2012-12-18       Impact factor: 4.942

Review 6.  Metastatic breast cancer: the treatment challenge.

Authors:  Stephen E Jones
Journal:  Clin Breast Cancer       Date:  2008-06       Impact factor: 3.225

7.  Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types.

Authors:  Julia Salzman; Charles Gawad; Peter Lincoln Wang; Norman Lacayo; Patrick O Brown
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

8.  Circular RNA biogenesis can proceed through an exon-containing lariat precursor.

Authors:  Steven P Barrett; Peter L Wang; Julia Salzman
Journal:  Elife       Date:  2015-06-09       Impact factor: 8.140

Review 9.  The fate of chemoresistance in triple negative breast cancer (TNBC).

Authors:  Elma A O'Reilly; Luke Gubbins; Shiva Sharma; Riona Tully; Matthew Ho Zhing Guang; Karolina Weiner-Gorzel; John McCaffrey; Michele Harrison; Fiona Furlong; Malcolm Kell; Amanda McCann
Journal:  BBA Clin       Date:  2015-03-12

10.  Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study.

Authors:  Tom Maishman; Ramsey I Cutress; Aurea Hernandez; Sue Gerty; Ellen R Copson; Lorraine Durcan; Diana M Eccles
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

View more
  57 in total

1.  Circular RNA hsa_circ_0001598 promotes programmed death-ligand-1-mediated immune escape and trastuzumab resistance via sponging miR-1184 in breast cancer cells.

Authors:  Li Huang; Jing Ma; Min Cui
Journal:  Immunol Res       Date:  2021-09-24       Impact factor: 2.829

2.  The Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer.

Authors:  Juan Xu; Xiyi Chen; Yu Sun; Yaqian Shi; Fang Teng; Mingming Lv; Chen Liu; Xuemei Jia
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

3.  Circular RNA circ-SLC7A6 acts as a tumor suppressor in non-small cell lung cancer through abundantly sponging miR-21.

Authors:  Yuan Wang; Fushuang Zheng; Zibo Wang; Jibin Lu; Hongyan Zhang
Journal:  Cell Cycle       Date:  2020-08-14       Impact factor: 4.534

Review 4.  MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells.

Authors:  Amir Sadra Zangouei; Maliheh Alimardani; Meysam Moghbeli
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

5.  Hsa_circ_0092276 promotes doxorubicin resistance in breast cancer cells by regulating autophagy via miR-348/ATG7 axis.

Authors:  Qiuli Wang; Dong Liang; Peng Shen; Yang Yu; Yuan Yan; Wei You
Journal:  Transl Oncol       Date:  2021-05-20       Impact factor: 4.243

Review 6.  Circular RNAs: new biomarkers of chemoresistance in cancer.

Authors:  Jiaqi Wang; Yi Zhang; Lianyu Liu; Ting Yang; Jun Song
Journal:  Cancer Biol Med       Date:  2021-03-19       Impact factor: 4.248

7.  Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28.

Authors:  Bing Chen; Yuting Sang; Xiaojin Song; Dong Zhang; Lijuan Wang; Wenjing Zhao; Yiran Liang; Ning Zhang; Qifeng Yang
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556

8.  Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.

Authors:  Hongliang Zang; Yuhui Li; Xue Zhang; Guomin Huang
Journal:  Thorac Cancer       Date:  2020-05-23       Impact factor: 3.500

9.  Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer.

Authors:  JunJie Yu; Si Sun; WeiPu Mao; Bin Xu; Ming Chen
Journal:  Onco Targets Ther       Date:  2021-06-21       Impact factor: 4.147

10.  Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.

Authors:  Jin Li; Xiaoping Qin; Ruishan Wu; Li Wan; Liang Zhang; Rui Liu
Journal:  J Cell Mol Med       Date:  2020-03-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.